Cite
Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).
MLA
Tang, Haowen, et al. “Expert Consensus on Sequential Surgery Following Conversion Therapy Based on Combination of Immune Checkpoint Inhibitors and Antiangiogenic Targeted Drugs for Advanced Hepatocellular Carcinoma (2024 Edition).” Bioscience Trends, Dec. 2024. EBSCOhost, https://doi.org/10.5582/bst.2024.01394.
APA
Tang, H., Zhang, W., Cao, J., Cao, Y., Bi, X., Zhao, H., Zhang, Z., Liu, Z., Wan, T., Lang, R., Sun, W., Du, S., Yang, Y., Lu, Y., Zeng, D., Wu, J., Duan, B., Lin, D., Li, F., … Lu, S. (2024). Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition). Bioscience Trends. https://doi.org/10.5582/bst.2024.01394
Chicago
Tang, Haowen, Wenwen Zhang, Junning Cao, Yinbiao Cao, Xinyu Bi, Haitao Zhao, Ze Zhang, et al. 2024. “Expert Consensus on Sequential Surgery Following Conversion Therapy Based on Combination of Immune Checkpoint Inhibitors and Antiangiogenic Targeted Drugs for Advanced Hepatocellular Carcinoma (2024 Edition).” Bioscience Trends, December. doi:10.5582/bst.2024.01394.